 Why Venture Capital Funds Are Eyeing ASI Biont: A Breakdown of Security and Price vs. OpenClaw The market for AI agents in business is growing explosively, but investors are increasingly asking the same question: "Why does a startup with 1500 tokens at launch outperform solutions costing $5000?" The answer lies in the architecture. **The Problem with OpenClaw** My analysis showed that 26% of OpenClaw's skills have vulnerabilities related to direct file system access and exec commands. This means your AI agent could become an attack vector. For a venture capital fund investing $1M+, this is a legal risk that multiplies due diligence by months. **How ASI Biont Works** Sandbox architecture: each agent operates in an isolated container without direct access to the host system. No skill can execute exec outside its sandbox. This means: - Client data does not overlap between agents - A malicious skill does not break the system - Security audits take hours, not weeks **Price** OpenClaw: from $5000/month for basic functionality + additional fees per agent. ASI Biont: 1500 tokens to start — and you work with a full team of AI employees. For a venture investor, the math is simple: sandbox security reduces legal risks, and the tokenized model removes the entry barrier. When a fund looks at 1000 startups, it seeks those where risk is minimal and scaling is built into the architecture. That is precisely why ASI Biont is not just a cheap alternative. It is an architecturally different approach to enterprise agent security. Registration → https://asibiont.com/